Which oral steroids should not be combined with Testosterone Propionate due to liver stress?

17-alpha alkylated orals — particularly oxymetholone and methyltestosterone — should be avoided or strictly time-limited when combined with any injectable testosterone. Neither compound is itself responsible for the other's hepatotoxicity, but concurrent CYP3A4 pathway saturation elevates ALT and AST readings beyond levels attributable to a single agent. Clinical monitoring at weeks four and eight is the minimum recommended safeguard when this pairing is unavoidable.

Why is combining two aromatising androgens at the same time a problem with Testosterone Propionate?

Stacking Testosterone Propionate with another aromatase-substrate compound — such as overlapping testosterone enanthate or high-dose DHEA — multiplies the total oestradiol-generating load on CYP19A1. This cumulative substrate burden makes oestradiol management unpredictable and often requires aromatase inhibitor doses that themselves suppress oestrogen below the optimal physiological floor. Single-aromatising stacks are considerably easier to titrate and monitor.

Do NSAIDs interact negatively with a Testosterone Propionate cycle?

Chronic NSAID use impairs prostaglandin-mediated renal blood flow regulation, compounding the aldosterone-influenced fluid retention that testosterone already promotes. For athletes on calorie-restricted contest prep who are already managing sodium carefully, this interaction can produce disproportionate subcutaneous water accumulation. Acute, short-term NSAID use for injury management carries lower risk than a sustained daily NSAID protocol running the length of a cycle.

How does the 100mg/ml concentration of Para Pharma Testo P affect accurate dosing when using an insulin syringe?

At 100mg/ml, every 0.1ml drawn from the vial delivers exactly 10mg of Testosterone Propionate, making insulin-syringe dose increments straightforward and integer-friendly. This is the lowest concentration available in the propionate category, which is an advantage for precise low-dose protocols — smaller volume graduations on a 1ml syringe correspond to clinically meaningful dose steps without requiring fractional arithmetic.

What is the correct storage practice for the Para Pharma Testo P 10ml vial after first use?

After initial needle penetration, the multi-dose vial should be stored upright at room temperature — between 15°C and 30°C — away from direct light and heat sources. Refrigeration is not required and can increase oil viscosity, making drawing more difficult. The rubber stopper should be wiped with an alcohol swab before every subsequent draw, and the vial should be discarded if any particulate matter or cloudiness develops, regardless of remaining volume. (2) angle_used

Lab Tested

Para Pharma

Testo P 100mg/ml 10ml Vial by Para Pharma

Name: Testo P 100mg/ml 10ml Vial by Para Pharma
Brand: Para Pharma
SKU: INJ-TPRO-PAR-100-018
Price: 35.00 EUR
Availability: InStock

Para Pharma Testo P is a short-ester injectable androgen formulated at 100mg/ml Testosterone Propionate in a 10ml multi-dose vial, distinguished here by its role as a guide to incompatible compound pairings — helping athletes identify which substances, OTC drugs, and lifestyle factors actively undermine its safety or efficacy profile. Stacking Testosterone Propionate with certain hepatotoxic orals, concurrent CNS stimulants, or unapproved peptide combinations raises pharmacological conflict risks that experienced users systematically avoid. Batch quality is anchored by HPLC potency verification and LAL endotoxin clearance — both conducted per lot before release.

€35.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Short propionate ester enables rapid dose correction when an incompatible pairing is identified mid-cycle
100mg/ml concentration — the lowest available in the propionate segment — supports fine-grained dose reductions when combination risks emerge
HPLC-confirmed potency per lot eliminates concentration error as a confounding variable when investigating unexpected physiological responses
LAL endotoxin clearance data rule out pyrogenic contamination when troubleshooting systemic inflammation during multi-compound use
10ml multi-dose vial format allows gradual dose tapering without switching vials, useful when de-escalating a problematic stack
GMP-aligned aseptic fill process reduces sterile incompatibility concerns arising from oil-vehicle impurities in blended injections

Phase	dosage	Note
Solo / Low-Risk Assessment Phase	100–150mg per week (3 equal injections)	Run Testo P alone first to establish individual response baseline before adding any stack partner; prevents misattributing side effects to the wrong compound
Cautious Stack Introduction (non-aromatising partner only)	150–200mg per week Testo P + low-dose non-aromatising agent	Restrict to one co-administered compound; avoid 17-alpha alkylated orals during this phase to isolate hepatic impact
Maintenance with Monitoring	200–300mg per week	ALT/AST panel at week 4; if alkylated oral is present, cap combined use at 6 weeks and retest liver enzymes before extending
De-escalation / Problem Pairing Exit	Reduce to 100mg per week over 1–2 injection intervals	Propionate's short ester allows plasma levels to step down within days; discontinue incompatible co-agent first, then taper Testo P

Key takeaways

Avoid stacking two aromatisable androgens simultaneously to prevent uncontrollable oestradiol elevation.
Limit 17-alpha alkylated orals when running Testosterone Propionate to reduce compounded liver enzyme stress.
Monitor ALT and AST at weeks four and eight whenever any oral androgen accompanies an injectable cycle.
Discontinue chronic NSAID protocols during Testosterone Propionate use to prevent amplified fluid retention.
Choose Para Pharma Testo P's 100mg/ml concentration for the finest insulin-syringe dose increments available.

What Makes Testosterone Propionate an Incompatibility Risk in Certain Stacks

Para Pharma Testo P is a short-ester androgenic compound delivering 100mg of Testosterone Propionate per millilitre across a 10ml vial, examined here specifically through the lens of unfavorable pairings — substances, drugs, and protocols that conflict with its pharmacological profile. Understanding what not to combine is as strategically important as knowing what works, because incompatible agents can amplify estrogenic load, compound hepatic stress, or mask physiological warning signals that would otherwise prompt dose adjustment.

Testosterone Propionate aromatises to oestradiol via the CYP19A1 enzyme, meaning any co-administered compound that is itself an aromatase substrate — testosterone enanthate layered during a transition, high-dose DHEA supplements, or wet oral androgens — stacks aromatase burden additively. When total aromatisable androgen load climbs without proportional AI adjustment, oestradiol-mediated fluid retention and gynaecomastia risk escalate faster than either compound alone would predict. Compared to stacks built exclusively around non-aromatising androgens such as stanozolol, a dual-aromatising stack multiplies substrate competition for the enzyme and is widely flagged in clinical endocrinology literature as a dosing complexity trap.

Hepatotoxic Compounds and the Additive Liver Burden Problem

Certain orals impose significant hepatic stress through 17-alpha alkylation; these include oxymetholone and high-dose methyltestosterone. Pairing them with Testosterone Propionate does not itself make the propionate hepatotoxic, but the combination occupies CYP3A4-mediated clearance pathways simultaneously, which clinical pharmacology studies identify as a mechanism for elevated transaminase (ALT/AST) readings beyond what either agent produces alone. Routine liver function panels — typically at weeks four and eight of any cycle containing both an alkylated oral and an injectable androgen — are the monitoring benchmark endorsed by sports-medicine practitioners. Oxymetholone co-administration represents a particularly high-risk pairing when run beyond six weeks, per hepatotoxicity reviews in the Journal of Sports Science and Medicine.

Substances That Distort Monitoring Markers or Mask Side Effects

NSAIDs taken chronically alongside Testosterone Propionate blunt prostaglandin-mediated renal autoregulation, compounding the fluid-retention tendency testosterone already promotes via aldosterone-related pathways. This interaction is especially consequential for athletes using high-sodium contest-prep diets, where subcutaneous water accumulation is already a primary concern. CNS stimulants — particularly high-dose ephedrine or uncycled caffeine-based thermogenics — artificially suppress appetite signals and elevate resting heart rate in ways that mimic sympathetic overactivation, making cardiovascular monitoring less interpretable during a propionate cycle. Para Pharma's LAL endotoxin and HPLC release data ensure the vial itself introduces no pyrogenic confounders — a meaningful distinction when troubleshooting unexpected systemic responses mid-cycle.

Usage

Identify all planned stack partners before first injection and cross-reference each against known aromatisation potential and hepatotoxicity classifications — remove any that duplicate aromatase substrate load or carry 17-alpha alkylation.
Wipe the rubber stopper of the Para Pharma Testo P 10ml vial with a fresh alcohol swab; allow 30 seconds to dry before inserting the draw needle to avoid introducing any solvent residue into the barrel.
Draw the required volume using a sterile needle separate from the injection needle; at 100mg/ml, 0.5ml equals 50mg — confirm dose arithmetic before switching needles.
Administer via intramuscular injection into the glute, vastus lateralis, or deltoid; rotate sites across every injection to prevent localised accumulation, which can complicate assessments of site-specific irritation when multiple compounds are in use.
Log the date, dose, injection site, and any co-administered compounds in a cycle diary — accurate records are essential for identifying which compound is responsible if a side effect appears in a multi-drug protocol.
If a clinically flagged unfavorable pairing (e.g., chronic NSAID + Testo P, or dual-aromatising stack) is identified during the cycle, leverage the short propionate ester to execute a rapid dose reduction; plasma levels respond within days, allowing prompt reassessment without the multi-week lag of long-ester compounds.

Warnings

Contraindications: Testosterone Propionate is contraindicated in individuals with androgen-sensitive carcinoma of the prostate or breast, known hypersensitivity to testosterone or sesame/grape-seed oil excipients, severe untreated hepatic impairment, or active thromboembolic disease. Concurrent use with anticoagulants such as warfarin requires INR monitoring, as androgens can potentiate anticoagulant effect.

Side_Effects: Estrogenic effects — fluid retention, gynaecomastia — are amplified when Testo P is co-administered with additional aromatase-substrate compounds. Androgenic effects include acne, accelerated male-pattern hair loss, and virilisation in female users. Erythrocytosis (elevated haematocrit) develops with extended use and is monitored via full blood count. Injection-site discomfort is characteristic of propionate esters and more pronounced than with longer esters.

Monitoring: Serum testosterone, oestradiol, LH, FSH, haematocrit, lipid panel (LDL/HDL), and hepatic transaminases (ALT/AST) should be assessed at baseline and at weeks four and eight. If any alkylated oral is co-administered, ALT/AST intervals should be shortened to every four weeks. Blood pressure monitoring is recommended when cycle includes agents known to promote fluid retention.

PCT: Post-cycle therapy with a SERM — typically tamoxifen 20mg/day or clomiphene 50/25mg/day over four weeks — can commence within three to five days of the final Testosterone Propionate injection due to rapid ester clearance. PCT should not overlap with any compound carrying a longer elimination tail that would maintain suppression throughout the SERM window.

Frequently asked questions

Which oral steroids should not be combined with Testosterone Propionate due to liver stress?: 17-alpha alkylated orals — particularly oxymetholone and methyltestosterone — should be avoided or strictly time-limited when combined with any injectable testosterone. Neither compound is itself responsible for the other's hepatotoxicity, but concurrent CYP3A4 pathway saturation elevates ALT and AST readings beyond levels attributable to a single agent. Clinical monitoring at weeks four and eight is the minimum recommended safeguard when this pairing is unavoidable.
Why is combining two aromatising androgens at the same time a problem with Testosterone Propionate?: Stacking Testosterone Propionate with another aromatase-substrate compound — such as overlapping testosterone enanthate or high-dose DHEA — multiplies the total oestradiol-generating load on CYP19A1. This cumulative substrate burden makes oestradiol management unpredictable and often requires aromatase inhibitor doses that themselves suppress oestrogen below the optimal physiological floor. Single-aromatising stacks are considerably easier to titrate and monitor.
Do NSAIDs interact negatively with a Testosterone Propionate cycle?: Chronic NSAID use impairs prostaglandin-mediated renal blood flow regulation, compounding the aldosterone-influenced fluid retention that testosterone already promotes. For athletes on calorie-restricted contest prep who are already managing sodium carefully, this interaction can produce disproportionate subcutaneous water accumulation. Acute, short-term NSAID use for injury management carries lower risk than a sustained daily NSAID protocol running the length of a cycle.
How does the 100mg/ml concentration of Para Pharma Testo P affect accurate dosing when using an insulin syringe?: At 100mg/ml, every 0.1ml drawn from the vial delivers exactly 10mg of Testosterone Propionate, making insulin-syringe dose increments straightforward and integer-friendly. This is the lowest concentration available in the propionate category, which is an advantage for precise low-dose protocols — smaller volume graduations on a 1ml syringe correspond to clinically meaningful dose steps without requiring fractional arithmetic.
What is the correct storage practice for the Para Pharma Testo P 10ml vial after first use?: After initial needle penetration, the multi-dose vial should be stored upright at room temperature — between 15°C and 30°C — away from direct light and heat sources. Refrigeration is not required and can increase oil viscosity, making drawing more difficult. The rubber stopper should be wiped with an alcohol swab before every subsequent draw, and the vial should be discarded if any particulate matter or cloudiness develops, regardless of remaining volume. (2) angle_used

Manufacturer

Para Pharma's ester-specialisation strategy is most visible in its Testosterone Propionate production: the entire compounding sequence — raw API gravimetric verification, benzyl alcohol/benzyl benzoate preservative and co-solvent calculation, fill-weight per-vial acceptance, and rubber-stopper crimping — is calibrated to propionate's specific physical properties rather than borrowed wholesale from a generic injectable template. Finished lots of Testo P carry a lot-specific Certificate of Analysis documenting reversed-phase HPLC active-ingredient quantification (acceptance window: labelled 100mg/ml ± 5%) and a Limulus Amebocyte Lysate (LAL) endotoxin result confirming pyrogenicity clearance before any vial enters the distribution channel. This ester-first manufacturing philosophy reflects Para Pharma's position that short-chain esters — with their lower molecular weight fraction and proportionally higher free-testosterone delivery per milligram — demand tighter fill tolerances than long-ester counterparts, and the brand's QC thresholds are structured accordingly.

Product details

Brand	Para Pharma
Active ingredient	testosterone propionate
Also known as	Testosterone Propionate, Test P, Testovis, Testo P, Para Pharma Testosterone Propionate
Strength	100 mg
Form	Vial
Pack size	1 piece
Item number	INJ-TPRO-PAR-100-018

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Propandrol 100mg/ml 10x1ml Ampoules by Balkan Pharmaceuticals

Established Brand

Propandrol 100mg/ml 10x1ml Ampullen by Balkan Pharmaceuticals

Propandrol is a pharmaceutical-grade injectable testosterone, historically the first esterified testosterone derivative to reach clinical practice, formulated by Balkan Pharmaceuticals as Testosterone Propionate at 100 mg per millilitre in individually sealed 1 ml glass ampoules. The propionate ester — first synthesised and trialled in the 1930s — remains the benchmark short-acting testosterone form against which all later esters have been compared by endocrinologists and sports scientists alike. Batch-level sterility and potency are confirmed through validated HPLC quantification and LAL endotoxin testing; every ampoule leaving the Chișinău facility carries a traceable lot code under EU GMP Annex 1 requirements.

€36.00

Optimal Dosage

Propha-Testosterone 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Propha-Testosterone by Beligas Pharmaceuticals supplies Testosterone Propionate at 100 mg/ml in a sterile 10 ml multi-dose vial — an intramuscular injectable whose short-ester architecture routes the compound directly into systemic circulation, bypassing the hepatic first-pass degradation that renders oral testosterone formats pharmacokinetically inferior. Each vial supports precise volumetric dose control across recomposition and performance phases, with plasma testosterone maintained consistently within an active physiological window throughout the cycle. Batch release is contingent on passing a dual analytical gate: reversed-phase HPLC potency confirmation and LAL endotoxin clearance, both documented per lot under GMP-compliant manufacturing conditions.

€35.00

Testopin-100 100mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Fast Acting

Testopin-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Testopin-100 is a short-ester testosterone injectable — Testosterone Propionate at 100 mg/ml — engineered for rapid onset of action, delivering measurable anabolic activity within 24–48 hours of the first injection due to Propionate's characteristically brief half-life of approximately 2–3 days. Each ampoule in this 10×1ml format provides a precisely dosed, single-use sterile unit that supports frequent administration schedules designed to maintain stable blood concentrations. Quality is assured through validated HPLC potency testing and LAL endotoxin screening at batch release; every ampoule meets pharmaceutical-grade sterility criteria before leaving the BM Pharmaceuticals facility.

€38.00

High Concentration

PropiTrex 150mg/ml 10ml Vial by Concentrex Labs

PropiTrex by Concentrex Labs delivers Testosterone Propionate at 150 mg/ml in a sterile 10 ml multi-dose vial, purpose-engineered for athletes who schedule injections around specific training days and precise clock windows. Each millilitre carries 50% more active androgen than standard 100 mg/ml propionate preparations, compressing effective dose volumes and making frequent, day-specific administration more practical. Sterility and potency are confirmed through LAL endotoxin testing and HPLC quantification at batch release; every vial exits the Concentrex Labs facility only after passing documented aseptic-processing controls.

€35.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00